In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM).

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo.

The drug is called ipilimumab. Before it came along there were no successful treatments for advanced melanoma and less than 3% of patients survived for five years. Now, with immunotherapy regimens ...

Nivolumab plus ipilimumab and nivolumab alone have been shown to improve survival, as compared with ipilimumab alone, in advanced melanoma. New research findings over 10 years of follow-up are ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody (mAb) ipilimumab showed a survival benefit in patients with advanced cancer—the first ever phase 3 trial to do so.

1 However, nivolumab and hyaluronidase-nvhy is not indicated in combination with intravenous ipilimumab. The approval is based on findings from the phase 3 CheckMate-67T trial (NCT04810078), a ...

A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% ...

Opdivo Qvantig can be used as monotherapy, monotherapy maintenance following treatment with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with chemotherapy or cabozantinib.